NCT06869746 Swiss Spinal Tumor Registry (Swiss-STR)
| NCT ID | NCT06869746 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Luzerner Kantonsspital |
| Condition | Spinal Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2023-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Swiss Spinal Tumor Registry is a prospective REDCap-based registry, collecting data of surgically treated patients with primary and metastatic tumors of the spine.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of primary spinal tumor * Diagnosis of secondary (metastatic) spinal tumor * Indication for surgical treatment is present * Patient age: =/\>18 years Exclusion criteria: * Withdrawal of consent * Withdrawal from initially planned surgical procedure * Patient age: \<18 years
Contact & Investigator
Edin Nevzati, MD
PRINCIPAL INVESTIGATOR
Frequently Asked Questions
Who can join the NCT06869746 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Spinal Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06869746 currently recruiting?
Yes, NCT06869746 is actively recruiting participants. Contact the research team at edin.nevzati@luks.ch for enrollment information.
Where is the NCT06869746 trial being conducted?
This trial is being conducted at Lucerne, Switzerland.
Who is sponsoring the NCT06869746 clinical trial?
NCT06869746 is sponsored by Luzerner Kantonsspital. The principal investigator is Edin Nevzati, MD. The trial plans to enroll 250 participants.